Status: Not yet recruiting
Long-Acting Injectable HIV PrEP PROs
The goal of this observational study is to learn about the real world effectiveness, patient satisfaction and clinical outcomes of LAI PrEP with lenacapavir (LEN) versus cabotegravir (CAB) through surveys and interviews. Participants receiving or initiating LAI PrEP part of their regular medical care will complete surveys and interviews at three study visits over the course of 12 months.
Participants needed: 128
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Anupama Raghuram MDUpdated: Jan 30, 2026Locations: 3
Eligibility criteria
Adults aged 18 and older [+5]
HIV diagnosis prior to enrollment [+4]